Life Edit Therapeutics to Present Data Demonstrating Therapeutic Potential of its Novel Gene Editing Platform
Moderna enters R&D collaboration for mRNA gene-editing therapies
One of Moderna's New Year's resolutions appears to have been to expand its genomics output. The latest move in this area sees the mRNA company pen a partnership with ElevateBio’s Life Edit Therapeutics with the aim of developing next-gen gene editing therapies for hard-to-treat diseases.
MORRISVILLE, N.C.--(BUSINESS WIRE)--Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB). Dr. Cavagnaro is an internationally recognized expert in science-based regulatory strategies and translation of research to preclinical and product development, with an emphasis on genetic medicines.